Astrazeneca (AZN) Long-Term Investments (2016 - 2026)

Astrazeneca has reported Long-Term Investments over the past 18 years, most recently at $2.4 billion for Q1 2026.

For Q1 2026, Long-Term Investments rose 44.72% year-over-year to $2.4 billion; the TTM value through Mar 2026 reached $2.4 billion, up 44.72%, while the annual FY2025 figure was $2.2 billion, 729.48% up from the prior year.
Long-Term Investments for Q1 2026 was $2.4 billion at Astrazeneca, up from $2.2 billion in the prior quarter.
Over five years, Long-Term Investments peaked at $2.4 billion in Q1 2026 and troughed at $147.0 million in Q4 2023.
A 5-year average of $1.4 billion and a median of $1.2 billion in 2023 define the central range for Long-Term Investments.
Biggest five-year swings in Long-Term Investments: surged 1444.93% in 2022 and later plummeted 86.21% in 2023.
Year by year, Long-Term Investments stood at $1.1 billion in 2022, then plummeted by 86.21% to $147.0 million in 2023, then skyrocketed by 82.31% to $268.0 million in 2024, then soared by 729.48% to $2.2 billion in 2025, then rose by 6.12% to $2.4 billion in 2026.
Business Quant data shows Long-Term Investments for AZN at $2.4 billion in Q1 2026, $2.2 billion in Q4 2025, and $2.0 billion in Q3 2025.

Peer Comparison